Investigational drug · Phase 3
Glumetinib
Also called: SCC244
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Non-Small Cell Lung Cancer, Recurrent or Metastatic NSCLC Patients With Classical EGFR Mutations Accompanied by MET Amplification or Overexpression, C-Met Exon 14 Mutation.
Phase 3Last checked: Nov 20, 2026Latest source record: Sep 8, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
5
5 still active
All registered trials
11
Any phase or sponsor naming "Glumetinib"
First trial start
2019
Jul 15, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Glumetinib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non-Small Cell Lung Cancer
- Recurrent or Metastatic NSCLC Patients With Classical EGFR Mutations Accompanied by MET Amplification or Overexpression
- C-Met Exon 14 Mutation
- Locally Advanced/Recurrent or Distant Metastasized Non-small Cell Lung Cancer With MET Overexpression
- Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Stomach and esophageal cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Glumetinib" as an intervention, largest first.
- Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer PatientsPivotal-lookingNot yet recruiting
Shanghai JMT-Bio Inc.Industry
NCT06908772 · 390 participants (planned) · Start Apr 1, 2025 · Primary completion Dec 31, 2028
Drug: Glumetinib Tablets; Osimertinib Mesylate Tablets and 1 more · For: Recurrent or Metastatic NSCLC Patients With Classical EGFR Mutations Accompanied by MET Amplification or Overexpression
- Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid TumorsPivotal-lookingRecruiting
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
NCT06947291 · 350 participants (planned) · Start Jun 4, 2025 · Primary completion Apr 30, 2027
Drug: Glumetinib Tablets; Docetaxel for Injection (Albumin-bound) · For: Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors
Sites: Hangzhou, China
- A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIsPivotal-lookingRecruiting
Shanghai JMT-Bio Inc.Industry
NCT06829459 · 350 participants (planned) · Start Apr 3, 2025 · Primary completion Feb 15, 2028
Drug: Glumetinib; Osimertinib mesylate and 2 more · For: Non-Small Cell Lung Cancer
Sites: Beijing, China
- A Study to Evaluate the Efficacy and Safety of the Combination of Glumetinib and Docetaxel(Albumin Bound)Verse Docetaxel for the Treatment of MET-overexpressed Non-small Cell Lung CancerPivotal-lookingNot yet recruiting
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
NCT06525350 · 256 participants (planned) · Start Jul 2024 · Primary completion Dec 25, 2026
Drug: Glumetinib tablets; HB1801 (docetaxel, albumin-bound) and 1 more · For: Locally Advanced/Recurrent or Distant Metastasized Non-small Cell Lung Cancer With MET Overexpression
Haihe Biopharma Co., Ltd.Industry
NCT04270591 · 183 participants (planned) · Start Jul 15, 2019 · Primary completion Oct 25, 2023
Drug: Glumetinib · For: C-Met Exon 14 Mutation
Sites: Louisville, Kentucky; Hefei, China; Beijing, China · 44 sites in all
Haihe Biopharma Co., Ltd.Industry
NCT03457532 · 177 participants · Start Dec 16, 2017 · Primary completion Sep 22, 2023
Drug: Gumarontinib Tablets · For: Advanced Solid Tumor
Sites: Shanghai, China
- Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer.Not yet recruiting
Cancer Institute and Hospital, Chinese Academy of Medical SciencesAcademic, hospital or other
NCT06452433 · 91 participants (planned) · Start Jun 1, 2024 · Primary completion Dec 12, 2027
Drug: gumarontinib; third-generation EGFR-TKI (Osimertinib, Almonertinib or Furmonertinib) · For: Non-small Cell Lung Cancer
Haihe Biopharma Co., Ltd.Industry
NCT04338243 · 70 participants (planned) · Start Nov 18, 2019 · Primary completion Dec 31, 2020
Drug: Glumetinib · For: Negative T790M Mutation and Met Amplification
Sites: Beijing, China
Haihe Biopharma Co., Ltd.Industry
NCT03466268 · 56 participants · Start Sep 14, 2017 · Primary completion Jan 9, 2023
Drug: Gumarontinib Tablets · For: Advanced Solid Tumor
Sites: Guangzhou, China
Liu HuangAcademic, hospital or other
NCT06980532 · 42 participants (planned) · Start Apr 25, 2025 · Primary completion Dec 30, 2028
Drug: Glumetinib Combined with Fruquintinib · For: Metastatic Colorectal Cancer
Sites: Wuhan, China
Newest research
PubMed records naming it or its code names, newest first.
- Structural analysis and crystallography-guided pharmacophore elucidation of capmatinib analogues as selective c-MET targeting anticancer agents.
Valipour M · Eur J Med Chem 2027
- Triple Genetic Alterations (EGFR Mutation, ALK Fusion, and MET Polysomy) in Gynecological Metastasis of Lung Adenocarcinoma Patient with Acquired Resistance to Furmonertinib: A Case Report.
Jiang Q, Sun R, Xu H, et al. · Curr Oncol 2026
- MET Amplification in Gallbladder Cancer: a Case Report on a Precision Medicine Approach with Glumetinib and Envafolimab.
Wu XJ, Nie X, Xu JF, et al. · J Gastrointest Cancer 2026
- New Onset Heart Failure Induced by Glumetinib: A Case Report.
Li X, Zhang W, Wang Y, et al. · Clin Ther 2026
- Short-term response to alectinib and rapid progression in a lung squamous cell carcinoma patient harboring an EML4-ALK fusion: a case report.
Li S, Du X, Zhang X, et al. · Transl Cancer Res 2026
- Advancing MET-aberrant NSCLC Therapy with Glumetinib: Pharmacokinetics, Efficacy, Safety, Drug Interactions, and Clinical Prospects.
Lu M, Yin X, Zhang Z · Curr Drug Metab 2026
Also in development for Non-Small Cell Lung Cancer
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.